ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
bullishMeituan
10 Oct 2019 09:20

Hang Seng Index Rebalance Preview - December 2019

The Hang Seng Indexes Company Limited (HSIL) will announce the results of the 2019 Q3 review of the Hang Seng Family of Indexes on 8 November. The...

Logo
607 Views
Share
01 Aug 2019 13:08

Hang Seng Index Rebalance Preview - September 2019

The Hang Seng Indexes Company Limited (HSIL) will announce the results of the 2019 Q2 review of the Hang Seng Family of Indexes on 16 August. The...

Logo
794 Views
Share
24 Jun 2019 14:22

HK Connect Ideas: Six Weeks of Inflows, BEW, Solars (2019-06-21)

In our weekly HK Connect Snippet series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as...

Logo
334 Views
Share
24 Jun 2019 06:29

Last Week in GER Research: Wuxi Biologics Placement, Budweiser APAC IPO, Slack and CIMC Direct

Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we update on the placement by Wuxi...

Logo
276 Views
Share
bullishWuxi Biologics
18 Jun 2019 23:07

WuXi Biologics Placement: Attractive in the Context of Market, Financials and Valuation

Wuxi Biologics (Cayman) Inc (2269 HK) is a global one-stop biologics services provider and often referred to as CRO (contract research...

Logo
568 Views
Share
x